JSP Pharmaceutical Manufacturing (Thailand) PCL

JSP Pharmaceutical Manufacturing (Thailand) PCL has a debt-to-equity ratio of 0.35, indicating a relatively conservative capital structure with a moderate reliance on debt financing. However, the company's liquidity position is assessed as medium, and its free cash flow is negative at -5.2 million THB, suggesting that capital expenditures are outpacing operating cash flow. The current ratio of 1.31 implies that the company has sufficient current assets to cover its short-term liabilities, but not by a large margin.

Profitability metrics for JSPM.BK are weak, with a return on equity of -0.28% and a return on assets of -0.18%, both of which are below the typical thresholds for healthy performance in the pharmaceutical industry. These figures indicate that the company is not generating returns for shareholders or effectively utilizing its assets to generate profit.

The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no material geographic diversification reported. This lack of diversification increases the company's exposure to regional economic and regulatory risks.

Looking ahead, JSPM.BK is expected to face challenges in improving its financial performance, as the company reported a net loss of 2.465 million THB in the latest reporting period. The outlook for the next fiscal year is uncertain, with no clear indication of a significant improvement in revenue or profitability.

The risk assessment for JSPM.BK highlights a liquidity risk due to negative net cash after subtracting total debt. While the company's dilution risk is currently low, the potential for future dilution remains a concern if the company needs to raise additional capital to fund operations or expansion.

Recent filings and transcripts do not indicate any major strategic shifts or new product launches that would significantly alter the company's trajectory. The company's capital expenditure of -16.623 million THB suggests ongoing investment in infrastructure or equipment, but the negative free cash flow indicates that these expenditures are not being offset by strong operating cash flow.

Net income surged 1,400% year-over-year to THB 67.9 million, signaling a dramatic recovery in profitability.

Revenue grew 22.5% year-over-year to THB 1.01 billion, demonstrating strong top-line expansion momentum.

Operating income jumped 1,239.1% to THB 124.8 million, indicating significant improvement in core operational efficiency.

The four-year revenue CAGR of 24.4% highlights consistent long-term growth potential for the business.

Gross profit reached THB 405.5 million, providing a substantial buffer for operating expenses and future investments.

The company carries a high credit risk flag, suggesting potential difficulties in meeting financial obligations.

Long-term debt increased to THB 381.2 million, adding leverage pressure despite recent earnings recovery.